1192 A novel MSLN×4–1BB bispecific antibody for solid tumor

1192 A novel MSLN×4–1BB bispecific antibody for solid tumor

Bibliographic Details
Main Authors:	Guodong Shen, Wenting Liu, Liansheng Cheng, Dayan Zhang, Weiming Zhou, Xiaoli Zeng
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

917 A novel B7H3×4–1BB bispecific antibody for solid tumor treatment
by: Qun Zhao, et al.
Published: (2023-11-01)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
by: Luigi Liguori, et al.
Published: (2022-11-01)

An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
by: Lian-sheng Cheng, et al.
Published: (2023-05-01)

1055 Heterodimeric Fc-fused IL12 shows potent antitumor activity and low toxicity
by: Pengfei Zhou, et al.
Published: (2023-11-01)

A novel carcinoembryonic antigen t cell bispecific antibody (cea tcb) for the treatment of solid tumors
by: Bacac, M, et al.
Published: (2016)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
by: Jim Middelburg, et al.
Published: (2021-01-01)

742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
by: David Hong, et al.
Published: (2023-11-01)

1384 LNK101, a highly differentiated T-cell engager (TCE) targeting CD3 and mesothelin (MSLN) in solid tumors
by: Linda Santiago, et al.
Published: (2023-11-01)

HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients
by: Christian M. Tegeler, et al.
Published: (2022-04-01)

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
by: Jim Middelburg, et al.
Published: (2024-01-01)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
by: Xi Chen, et al.
Published: (2023-06-01)

1171 CLN-418, a clinical-stage B7H4 x 4–1BB bispecific antibody with potential to treat patients with a wide range of solid tumors
by: Yun He, et al.
Published: (2023-11-01)

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
by: Lian-sheng Cheng, et al.
Published: (2022-09-01)

1342 A novel dual CAB Nectin-4 x CD3 bispecific antibody targeting solid tumors
by: Jing Wang, et al.
Published: (2023-11-01)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
by: Gabriele Antonarelli, et al.
Published: (2021-08-01)

Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors
by: Adam R. Root, et al.
Published: (2021-01-01)

792 Givastomig, a novel Claudin18.2/4–1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer
by: Ke Xu, et al.
Published: (2023-11-01)

Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs
by: Yuanyuan SONG, et al.
Published: (2022-09-01)

MSLN induced EMT, cancer stem cell traits and chemotherapy resistance of pancreatic cancer cells
by: Jili Hu, et al.
Published: (2024-04-01)

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
by: Thomas Poiret, et al.
Published: (2023-02-01)

Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017-04-01)

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
by: Rui Sun, et al.
Published: (2021-06-01)

Bispecific antibodies: a novel approach for targeting prominent biomarkers
by: Akshita Gupta, et al.
Published: (2020-11-01)

Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.
by: Gilliland, L, et al.
Published: (1988)

Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors
by: Yuan Yuan, et al.
Published: (2024-05-01)

Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody
by: Jun Fang, et al.
Published: (2023-07-01)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
by: Yang Zhang, et al.
Published: (2023-06-01)

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
by: Diana C. Simão, et al.
Published: (2023-02-01)

Dlaczego rok 1192 stał się początkiem historii miasta Czarnkowa?
by: Wojciech Nowacki
Published: (2010-12-01)

A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024-12-01)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
by: Lijun Wu, et al.
Published: (2022-05-01)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
by: Camila Ordóñez-Reyes, et al.
Published: (2022-06-01)

1186 Engineering bispecific dual-antagonist antibodies for novel cancer therapies
by: Ankita Srivastava, et al.
Published: (2023-11-01)

Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
by: Jared Weddell
Published: (2023-11-01)

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL
by: Y. Song, et al.
Published: (2022-06-01)

The Exchange of Gifts between Christians and Muslims on Lusignan and Venetian Cyprus 1192–1517
by: Nicholas Coureas
Published: (2023-09-01)

845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade
by: Seung Hyuck Jeon, et al.
Published: (2023-11-01)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
by: Toshihiko Doi, et al.
Published: (2022-10-01)

Bispecific Antibodies for IFN-β Delivery to ErbB2<sup>+</sup> Tumors
by: Vladislav S. Rybchenko, et al.
Published: (2021-12-01)

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
by: Nai-Kong V Cheung, et al.
Published: (2022-01-01)